Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 86

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 86
---
 notice from WVURC; commit a material breach that is not cured, or capable of being cured, within ninety (90) days after receipt of notice from WVURC; or challenge the validity of any of the WVU Patents before a court or other administrative agency in any jurisdiction. Upon any termination prior to the expiration of the WVU Agreement for any reason, all licenses and rights granted pursuant to the agreement will automatically terminate.

25

The following is a summary of the patent rights licensed from Moffitt Cancer Center and WVURC:

    Patent Family
     
    Description
     
    Application/Publication/Patent Number
     
    Filing Date
     
    Issue Date/Status
     
    Earliest Expected Expiration Date
     
    Type of Patent Protection

    DNA Vector and Transformed Tumor Cell Vaccines
     
    Whole cell and DNA cancer vaccines
     
    PCT/US2015/018688 (WO 2015/134577)
    03/04/2015
     
    Nationalized in CH, DE, DK, EP, FR, GB, HK, IE, NL, NO, SE, US
     
    03/04/2035 
     
    Use CompositionComposition/use

      US 9,555,088 US9,839,680 US10,391,158 US10,751,400 
     07/07/2016 01/30/2017 12/11/2017 08/26/2019
     
      Issued 01/31/2017 Issued 12/12/2017 Issued 08/27/2019 Issued 08/25/2020
     
    3/4/20353/4/20353/4/20353/4/2035

    Cancer Vaccine Comprising mRNA Encoding a M-Like-Protein
     
    Next generation cancer vaccine using mRNA encoding a bacterial antigen to prime anti- cancer immune responses
     
    PCT/US2016/033235 (WO 2016/187407)     US 9,636,388 US10,682,401 US18/060,605 
    05/19/2016  07/28/201605/01/201712/01/2022 
    Nationalized in AU, CA, CH,CN, DE, DK,